Salarius Net Income From Continuing Ops from 2010 to 2025
| SLRX Stock | USD 0.86 0.06 6.52% |
Net Loss | First Reported 2015-03-31 | Previous Quarter -972.1 K | Current Value -1.5 M | Quarterly Volatility 3.5 M |
Check Salarius Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Salarius Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 150.6 K, Depreciation And Amortization of 8.6 K or Interest Expense of 281.6 K, as well as many indicators such as Price To Sales Ratio of 97.37, Dividend Yield of 0.0011 or PTB Ratio of 1.11. Salarius financial statements analysis is a perfect complement when working with Salarius Pharmaceuticals Valuation or Volatility modules.
Salarius | Net Income From Continuing Ops |
Latest Salarius Pharmaceuticals' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Salarius Pharmaceuticals over the last few years. It is Salarius Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Salarius Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Salarius Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (22,453,729) | |
| Geometric Mean | 18,705,026 | |
| Coefficient Of Variation | (50.58) | |
| Mean Deviation | 9,841,641 | |
| Median | (29,213,658) | |
| Standard Deviation | 11,356,850 | |
| Sample Variance | 129T | |
| Range | 33.9M | |
| R-Value | 0.67 | |
| Mean Square Error | 75.4T | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | 1,608,429 | |
| Total Sum of Squares | 1934.7T |
Salarius Net Income From Continuing Ops History
About Salarius Pharmaceuticals Financial Statements
Salarius Pharmaceuticals investors use historical fundamental indicators, such as Salarius Pharmaceuticals' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Salarius Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -5.6 M | -5.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Salarius Stock Analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.